Market Intelligence, Clinical Progress, and High-Purity Reagents for Neurodegenerative Disease Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for SARM1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | SARM1 (Full-Length & Active TIR Domain) Recombinant Protein High purity (>95%), Endotoxin controlled. Sequence Verified. Eukaryotic expression for correct folding. |
View SARM1 Products |
| Gene Delivery | SARM1 Promise-ORF / Lentivirus Full-length human SARM1 ORF for stable cell line generation (e.g., in PC12 or SH-SY5Y). |
View SARM1 Products |
| Benchmark Ab | Anti-SARM1 Recombinant Antibody Sequence-verified positive control for Western Blot, IHC, and IP assays. |
View SARM1 Products |
| Validator | SARM1 siRNA Set Target-specific knockdown pool for functional validation of axonal protection. |
View SARM1 Products |
| Related Target A | NMNAT2 Essential axonal survival factor. Loss of NMNAT2 triggers SARM1 activation via NMN accumulation. |
View NMNAT2 Products |
| Related Target B | DLK (MAP3K12) Upstream kinase in the axonal degeneration signaling pathway that regulates SARM1 activity. |
View DLK Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Enzymatic Assay Stability (NADase Activity) | Recombinant SARM1 active TIR domain and full-length proteins with verified theoretical MW and high purity (>95% by SDS-PAGE) to ensure consistent baseline NAD+ cleavage rates. |
| Auto-Inhibition Modeling | Availability of wild-type and specific mutant proteins (e.g., E642A catalytically inactive mutant) for baseline and mechanism-of-action (MoA) studies. |
| Lack of Controls | Sequence-derived recombinant benchmark antibodies included to establish reliable assay baselines. |
| False Positives in Knockdown | Sequence-verified siRNA pools included for target specificity confirmation in phenotypic assays. |
Live SARM1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for SARM1 therapeutics is intensifying, with major players shifting focus from traditional neuroprotective approaches to targeted enzymatic inhibition. SARM1 is a multidomain enzyme containing an armadillo repeat motif (ARM) domain, sterile alpha motif (SAM) domains, and a Toll/interleukin-1 receptor (TIR) domain. It acts as the primary executioner of programed axonal degeneration (Wallerian degeneration). Upon injury or disease-induced depletion of NMNAT2, the metabolite NMN accumulates and binds to SARM1, triggering conformational changes that activate its intrinsic NADase activity. This leads to rapid NAD+ depletion, metabolic collapse, and axonal axonopathy.
As first-generation small molecule inhibitors and gene therapies reach early clinical phases, the next wave of R&D is targeting allosteric modulation and genetic silencing. Developing highly selective inhibitors requires robust, purified proteins that preserve the delicate balance between the auto-inhibited state and the active octameric state.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Disarm Therapeutics (Eli Lilly), Nura Bio, Maze Therapeutics | ALS, CIPN, Diabetic Neuropathy | Enzymatic NADase Assay (Need high-purity TIR domain and E642A mutant proteins) |
| Gene Therapy (AAV/shRNA) | Janssen, Academic Institutions | Glaucoma, Traumatic Brain Injury | In vitro validation of knockdown (Need SARM1 Lentivirus and siRNA validation tools) |
| Antisense Oligonucleotides (ASO) | Ionis Pharmaceuticals | Peripheral Neuropathy, Neurodegenerative Diseases | Endogenous target knockdown monitoring (Need high-affinity sequence-verified benchmark antibodies) |